These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1079054)

  • 21. Synthesis and pharmacological properties of some N-aroylhomotryptamines.
    Misztal S; Boksa J; Chojnacka-Wójcik E; Tatarczyńska E
    Pol J Pharmacol Pharm; 1979; 31(2):149-56. PubMed ID: 315061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of 4H-3-methylcarboxamide-1,3-benzoxazine-2-one (FI 6654) on monoaminoxidase and cerebral 5-HT.
    Suchowsky GK; Pegrassi L; Moretti A; Bonsignori A
    Arch Int Pharmacodyn Ther; 1969 Dec; 182(2):332-40. PubMed ID: 5308944
    [No Abstract]   [Full Text] [Related]  

  • 23. N-substituted cyclopropylamines as monoamine oxidase inhibitors. Structure-activity relationships. Dopa potentiation in mice and in vitro inhibition of kynuramine oxidation.
    Mills J; Kattau R; Slater IH; Fuller RW
    J Med Chem; 1968 Jan; 11(1):95-7. PubMed ID: 4384132
    [No Abstract]   [Full Text] [Related]  

  • 24. Selective monoamine oxidase inhibitors. II. 4-aminophenylalkylamine derivatives.
    Florvall L; Ask AL; Ross SB; Ogren SO; Holm AC
    Acta Pharm Suec; 1983; 20(4):255-70. PubMed ID: 6605662
    [No Abstract]   [Full Text] [Related]  

  • 25. Monoamine oxidase inhibitory and anticonvulsant properties of 1,2,4-trisubstituted 5-imidazolones.
    Verma M; Chaturvedi AK; Chaudhari A; Parmar SS
    J Pharm Sci; 1974 Nov; 63(11):1740-4. PubMed ID: 4427234
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of imipramine, desipramine and monoamine oxidase inhibitors on the metabolism and psychomotor stimulant actions of d-amphetamine in mice.
    Lew C; Iversen SD; Iversen LL
    Eur J Pharmacol; 1971 May; 14(4):351-9. PubMed ID: 4400534
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of 2,3-dioxoindoline on a behavioral syndrome after tryptamine in pargyline-treated mice.
    Kästner I; Müller M
    Pharmazie; 1981 Oct; 36(10):711. PubMed ID: 7312929
    [No Abstract]   [Full Text] [Related]  

  • 28. Discriminant analysis of the relationship between physical properties and the inhibition of monoamine oxidase by aminotetralins and aminoindans.
    Martin YC; Holland JB; Jarboe CH; Plotnikoff N
    J Med Chem; 1974 Apr; 17(4):409-13. PubMed ID: 4830537
    [No Abstract]   [Full Text] [Related]  

  • 29. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.
    Heikkila RE; Duvoisin RC; Finberg JP; Youdim MB
    Eur J Pharmacol; 1985 Oct; 116(3):313-7. PubMed ID: 3935467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of monoamine oxidase by N-(phenoxyethyl)cyclopropylamines. Correlation of inhibition with Hammett constants and partition coefficients.
    Fuller RW; Marsh MM; Mills J
    J Med Chem; 1968 Mar; 11(2):397-8. PubMed ID: 5663643
    [No Abstract]   [Full Text] [Related]  

  • 31. [Does potentiation of the excito-motor effects of tryptamine in the rat and mouse enable one to measure the action of monoamine oxidase inhibitors?].
    Denys A; Levy J; Michel-Ber E
    J Physiol (Paris); 1965; 57(4):457-74. PubMed ID: 5850025
    [No Abstract]   [Full Text] [Related]  

  • 32. An interaction between the antidepressant drugs desipramine and modaline sulphate.
    Jori A; Pugliatti C
    J Pharm Pharmacol; 1967 Dec; 19(12):853-5. PubMed ID: 4383656
    [No Abstract]   [Full Text] [Related]  

  • 33. [Synthesis, pharmacological properties and effect upon monoamine oxidase activity of some sydnoneimines].
    Iashunskiĭ VG; Mashkovskiĭ MD; Gorkin VZ; Kholodov LE; Al'tshuler RA; Polezhaeva AI; Verevkina IV
    Farmakol Toksikol; 1970; 33(3):297-302. PubMed ID: 5453024
    [No Abstract]   [Full Text] [Related]  

  • 34. Selective monoamine oxidase inhibitor drugs as aids in evaluating the role of type A and B enzymes.
    Fuentes JA; Neff NH
    Neuropharmacology; 1975 Nov; 14(11):819-25. PubMed ID: 1207877
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of the inhibitory effects of propargylamine and pargyline on brain and liver monoamine oxidase activity.
    Abeles RH; Tashjian AH
    Biochem Pharmacol; 1975 Jan; 24(2):307-8. PubMed ID: 1111545
    [No Abstract]   [Full Text] [Related]  

  • 36. Dose-response effects of beta-phenylethylamine on stereotyped behavior in pargyline-pretreated rats.
    Moja EA; Stoff DM; Gillin JC; Wyatt RJ
    Biol Psychiatry; 1976 Dec; 11(6):731-42. PubMed ID: 1033771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs.
    Neff NH; Yang HY
    Life Sci; 1974 Jun; 14(11):2061-74. PubMed ID: 4603266
    [No Abstract]   [Full Text] [Related]  

  • 38. Influence of substrate in the inhibition of rat liver and brain monoamine oxidase.
    Fuller RW
    Arch Int Pharmacodyn Ther; 1968 Jul; 174(1):32-7. PubMed ID: 4386711
    [No Abstract]   [Full Text] [Related]  

  • 39. N-methyl-n-2-propynyl-l-indanamine. A protent monoamine oxidase inhibitor.
    Huebner CF; Donoghue EM; Plummer AJ; Furness PA
    J Med Chem; 1966 Nov; 9(6):830-2. PubMed ID: 5972038
    [No Abstract]   [Full Text] [Related]  

  • 40. Kinetic studies and effects in vivo of a new monoamine oxidase inhibitor, N-[2-(o-chlorophenoxy)-ethyl]-cyclopropylamine.
    Fuller RW
    Biochem Pharmacol; 1968 Oct; 17(10):2097-106. PubMed ID: 5696879
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.